Skip to content

Covid-19 Predictors: Safety of Gynecological Oncology Patients Undergoing Systemic Cancer Therapy

COVID-19-Prädiktoren: Klinische Studie Zur Sicherheit Von Gynäkologisch Onkologischen Patientinnen Unter Onkologischer Systemtherapie - CO-SI-ONKO-Studie

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05043220
Acronym
CO-SI-ONKO
Enrollment
100
Registered
2021-09-14
Start date
2021-09-29
Completion date
2025-04-30
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Telemedicine

Brief summary

We designed a monocenter prospective cohort study using PROM via app and remote monitoring via pho-toplethysmography (PPG). The application of these technologies enables an early detection of infections and therefore initiation of medical interventions. The study is conducted as feasibility analysis; primary endpoints are adherence (according to wearing time) and technical robustness.

Interventions

DEVICEPPG and PROM

description will follow

Sponsors

Technical University of Munich
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* gynecological cancer * indication for systemic cancer therapy * patients who are legally competent and able to understand and follow instructions of the study staff * present informed consent

Exclusion criteria

* no use if internet or applications * persons who are in a dependency or employment relationship with the study center * positive proof of COVID-19 * affection of the external auditory canal

Design outcomes

Primary

MeasureTime frameDescription
Compliance3 monthsCompliance is defined as wearing time of the in-ear-sensor.
robustness of the ppg-signal3 monthsnumber and duration of the ppg-signal transmitted

Secondary

MeasureTime frameDescription
infections3 monthsdetection of infesctions via suspected ppg-signal transmitted or PRO-data. This results in blood test zu verify acute infections.
therapy modifications3 monthsdose-reductions (%), postponing of therapy cycles (time in days between actual and plannend date), therapy discontinuation
number of correct- and false-positive alerts3 monthsdefinition via comparison of alerts with clinical data
OS; PFS3 monthstime between study inclusion and death; time between study inclusion and proven increasing tumor mass (number of days)
health-related costs3 monthscost-effectiveness analysis
effect on quality of life3 monthschange in minimum 9 points in the EORTC QLQ-C30-questionnaire is evaluated as significant change. In questions 1-28: 28-112 points can be achieved: higher scores are associated with a worse outcome. In questions 29-30:2-14 points can be achieved: higher scores are associated with a better outcome.
number of contacts and hospitalization rates3 monthsdefinition via comparison of alerts and resulting contacts and hospitalization rates with clinical data

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026